• Prescribing Information
  • Patient Site
  • Sign up for emails
  • Request a representative
Approved use for Talicia

Talicia is indicated for the treatment of Helicobacter pylori infection in adults

Talicia
  • About
    • H. pylori resistance
    • How Talicia works
  • Efficacy
    • Talicia eradication rates
    • Traditional therapy failure rates
  • Safety
  • Simple Dosing
  • HCP Resources
    • Request information
    • Patient resources
    • FAQs
  • About
    ▽
    • H. pylori resistance
    • How Talicia works
  • Efficacy
    ▽
    • Talicia eradication rates
    • Traditional therapy failure rates
  • Safety
  • Simple Dosing
  • HCP Resources
    ▽
    • Request information
    • Patient resources
    • FAQs

Sitemap

Home HCP

About

  • H. pylori resistance
  • How Talicia works

Efficacy

  • Talicia eradication rates
  • Traditional therapy failure rates

Safety

Simple Dosing

HCP Resources

  • Request information
  • Patient resources
  • FAQs
+ -
Important Safety Information

Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycins.

Talicia is contraindicated in patients receiving delavirdine, voriconazole or rilpivirine-containing products.

Serious and occasionally fatal hypersensitivity reactions have been reported with the components of Talicia: omeprazole, amoxicillin and rifabutin.

Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the components of Talicia: rifabutin, amoxicillin, and omeprazole.

Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Talicia.

Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.

Clostridioides difficile-associated diarrhea has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.

Talicia may cause fetal harm and is not recommended for use in pregnancy. It may also reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.

Talicia should not be used in patients with hepatic impairment or severe renal impairment.

Cutaneous lupus erythematosus and systemic lupus erythematosus have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.

The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.

Please also see complete Prescribing Information.

HCP Address

RedHill Biopharma Inc. (U.S. Office)
8311 Brier Creek Pkwy, Suite 105-161
Raleigh, NC 27617
Tel: +1-984-444-7010
Fax: +1-919-800-3403
info@redhillus.com

Back to top
  • Contact Us
  • RedHill Biopharma US Corporate Site
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Sitemap
  • Prescribing Information

Trademarks are owned by or licensed to RedHill Biopharma Inc. or its related companies.

©2024 RedHill Biopharma Ltd. All rights reserved. US-TAL-340 05/2024

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

GO BACK

I am a US health care professional

CONTINUE

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

GO BACK

I am a US health care professional

CONTINUE